Martin Schrappe Selected Research

Residual Neoplasm

1/2021	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
1/2021	Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.
11/2019	Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study.
1/2019	Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study.
1/2019	Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.
10/2018	Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia.
1/2018	Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
1/2016	Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.
4/2015	Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
1/2014	High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Schrappe Research Topics

Disease

107	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 01/2001
36	Leukemia 01/2022 - 04/2003
32	Residual Neoplasm 01/2021 - 12/2002
26	Neoplasms (Cancer) 01/2022 - 07/2002
20	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 06/2002
9	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 07/2002
6	Pathologic Complete Response 01/2021 - 02/2006
5	Philadelphia Chromosome 12/2018 - 11/2010
4	Hypersensitivity (Allergy) 01/2022 - 01/2011
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 01/2004
4	Infections 04/2015 - 09/2004
3	Down Syndrome (Down's Syndrome) 01/2020 - 10/2008
3	Hematologic Neoplasms (Hematological Malignancy) 01/2017 - 01/2001
3	T-Cell Leukemia (Leukemia, T Cell) 07/2012 - 11/2008
3	Neuroblastoma 01/2011 - 09/2004
2	Aneuploidy (Aneuploid) 08/2021 - 12/2019
2	Brain Neoplasms (Brain Tumor) 01/2021 - 08/2009
2	Second Primary Neoplasms (Neoplasms, Second) 01/2021 - 11/2011
2	Genetic Predisposition to Disease (Genetic Predisposition) 11/2019 - 11/2013
2	Osteonecrosis (Kienbock's Disease) 01/2019 - 10/2018
2	Central Nervous System Diseases (CNS Diseases) 01/2017 - 02/2005
2	Glucocorticoid Receptor Deficiency 04/2010 - 04/2009
1	Pancreatitis 10/2021
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2021
1	Chromosome Aberrations (Chromosome Abnormalities) 04/2020

Drug/Important Bio-Agent (IBA)

14	Pharmaceutical PreparationsIBA 01/2020 - 06/2002
10	Prednisone (Sone)FDA LinkGeneric 01/2021 - 11/2003
9	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 12/2002
9	Proteins (Proteins, Gene)FDA Link 06/2018 - 11/2003
8	Asparaginase (Elspar)FDA Link 01/2022 - 01/2011
7	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 02/2005
6	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2017
6	Imatinib Mesylate (Gleevec)FDA Link 12/2018 - 09/2012
6	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2018 - 12/2002
6	Immunoglobulins (Immunoglobulin)IBA 01/2018 - 12/2002
5	AntibodiesIBA 01/2022 - 01/2011
5	pegaspargase (Oncaspar)FDA Link 03/2021 - 03/2013
5	Biological ProductsIBA 11/2019 - 10/2007
5	Dexamethasone (Maxidex)FDA LinkGeneric 12/2017 - 06/2002
5	GlucocorticoidsIBA 04/2010 - 11/2003
4	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 09/2005
3	Messenger RNA (mRNA)IBA 10/2020 - 05/2010
3	Phosphotransferases (Kinase)IBA 01/2020 - 04/2010
3	Tyrosine Kinase InhibitorsIBA 11/2018 - 03/2014
3	Biomarkers (Surrogate Marker)IBA 10/2018 - 06/2013
3	AntigensIBA 01/2018 - 01/2012
3	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 06/2013 - 01/2005
3	EnzymesIBA 11/2011 - 03/2005
2	daratumumabIBA 01/2022 - 01/2019
2	MicroRNAs (MicroRNA)IBA 11/2021 - 01/2017
2	blinatumomabIBA 04/2021 - 01/2019
2	ChromatinIBA 01/2020 - 11/2019
2	Transcription Factors (Transcription Factor)IBA 12/2019 - 01/2018
2	CytokinesIBA 12/2019 - 10/2008
2	ProteomeIBA 12/2019 - 06/2013
2	Dasatinib (BMS 354825)FDA Link 11/2018 - 01/2017
2	Small Interfering RNA (siRNA)IBA 06/2018 - 01/2015
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2017 - 09/2005
2	ruxolitinibIBA 01/2017 - 09/2016
2	Janus Kinase InhibitorsIBA 09/2016 - 10/2008
2	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 02/2016 - 03/2005
2	Interleukin-15 (Interleukin 15)IBA 05/2015 - 10/2007
2	Thymidylate SynthaseIBA 06/2013 - 03/2003
2	Interleukin-7 (Interleukin 7)IBA 05/2011 - 06/2002
2	Cytokine Receptors (Cytokine Receptor)IBA 05/2011 - 07/2010
2	dinutuximabIBA 01/2011 - 09/2004
2	Rituximab (Mabthera)FDA Link 07/2010 - 02/2006
2	Cytarabine (Cytosar-U)FDA LinkGeneric 07/2010 - 07/2007
2	thiopurine methyltransferase (thiopurine S-methyltransferase)IBA 08/2009 - 03/2005
2	Lymphotoxin-alpha (Lymphotoxin)IBA 06/2009 - 01/2001
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2009 - 01/2001
2	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 04/2009 - 11/2003
2	Codon (Codons)IBA 01/2005 - 07/2002
1	venetoclaxIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Dacarbazine (DIC)FDA LinkGeneric 08/2021
1	Busulfan (Busulfex)FDA Link 01/2021
1	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2021
1	AnthracyclinesIBA 01/2021
1	treosulfanIBA 01/2021
1	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 01/2021
1	Thioguanine (Tioguanine)FDA Link 01/2021
1	fludarabineIBA 01/2021
1	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2021
1	Type II Tumor Necrosis Factor ReceptorsIBA 10/2020

Therapy/Procedure

58	Therapeutics 01/2022 - 01/2001
30	Drug Therapy (Chemotherapy) 01/2022 - 12/2002
15	Stem Cell Transplantation 01/2021 - 05/2004
13	Hematopoietic Stem Cell Transplantation 01/2021 - 01/2004
7	Radiotherapy 01/2021 - 01/2006
6	Aftercare (After-Treatment) 01/2021 - 04/2003
4	Immunotherapy 01/2022 - 05/2004
4	Cranial Irradiation 09/2009 - 01/2004
3	Homologous Transplantation 01/2019 - 06/2008
3	Transplantation 01/2016 - 06/2008
3	Ligation 11/2015 - 03/2013
3	Remission Induction 11/2013 - 01/2011
2	Induction Chemotherapy 01/2020 - 06/2009
2	Heterologous Transplantation (Xenotransplantation) 01/2020 - 08/2011
2	Combination Drug Therapy (Combination Chemotherapy) 08/2011 - 01/2009